Latest Articles

Publication Date
Endometrial Ablation Market to Benefit from Technological Innovations and Healthcare Modernization - openPR.com

Endometrial Ablation Market to Benefit from Technological Innovations and Healthcare Modernization openPR.com

Published: April 24, 2025, 6:22 a.m.
MYB Proto-Oncogene Like 2 Identified as a Biomarker for Uterine Corpus Endometrial Carcinoma: evidence from Bioinformatics and Clinical Validation - Frontiers

MYB Proto-Oncogene Like 2 Identified as a Biomarker for Uterine Corpus Endometrial Carcinoma: evidence from Bioinformatics and Clinical Validation Frontiers

Published: April 23, 2025, 2:47 p.m.
Intrauterine infusion of autologous platelet-rich plasma modulates endometrial immune status and improves pregnancy outcomes in patients with persistent chronic endometritis - Frontiers

Intrauterine infusion of autologous platelet-rich plasma modulates endometrial immune status and improves pregnancy outcomes in patients with persistent chronic endometritis Frontiers

Published: April 23, 2025, 10:28 a.m.
AI diagnoses endometrial cancer with high accuracy - Lab + Life Scientist

AI diagnoses endometrial cancer with high accuracy Lab + Life Scientist

Published: April 23, 2025, 1:24 a.m.
Ultrasound-based model finds endometrial malignancies - AuntMinnie

Ultrasound-based model finds endometrial malignancies AuntMinnie

Published: April 22, 2025, 5:51 p.m.
Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer - OncLive

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer OncLive

Published: April 21, 2025, 1:17 p.m.
Cadonilimab-Lenvatinib Combo Exhibits Activity in Advanced Endometrial Cancer - Oncology Nurse Advisor

Cadonilimab-Lenvatinib Combo Exhibits Activity in Advanced Endometrial Cancer Oncology Nurse Advisor

Published: April 21, 2025, 4 a.m.
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer OncLive

Published: April 18, 2025, 3:54 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!